欧洲疾控中心-从疫区返回的献血者登革热病毒的延期标准和检测策略（英）

Suggested citation: European Centre for Disease Prevention and Control. Deferral criteria and testing strategies for dengue virus in blood donors returning from affected areas – survey results. Stockholm: ECDC; 2025. Stockholm, August 2025 ISBN: 978-92-9498-815-7. TQ: 01-25-045-EN-N. DOI: 10.2900/4266554 © European Centre for Disease Prevention and Control, 2025. Reproduction is authorised, provided the source is acknowledged. Key findings To support discussions with the ECDC network on substances of human origin (SoHO-Net), ECDC conducted a survey among members of the SoHO-Net blood group on the donor assessment and deferral strategies for blood donors in the European Union/European Economic Area (EU/EEA) countries with regard to dengue virus. This report presents the results of the survey. • While 91% of the responding EU/EEA countries have deferral criteria for blood donors returning from dengue-endemic areas, only 55% have specific criteria for those returning from affected non-endemic areas within the EU/EEA. • For countries that defer donors returning from endemic countries or affected areas in non-endemic countries, the deferral period is consistently 28 days. For donors with a confirmed dengue diagnosis, the deferral period is reported as 120 days. • Different trigger criteria are used to implement safety measures for prospective donors returning from affected areas with local dengue outbreaks in EU countries. Five countries implement safety measures when there is at least one locally-acquired case in an area with an active cluster of dengue, while six countries implement measures on a case-by-case basis. • Deferral of prospective donors who have travelled to a dengue affected area is the most commonly used blood safety measure for prevention of transfusion-transmitted dengue. Nucleic Acid Testing (NAT) for dengue is rarely reported as a screening tool. • There is no standardised definition for the geographical scope of an ‘affected area’ for local dengue outbreaks in EU countries, with risk levels being applied at the country, regional, or municipal level by different Member States. Conclusions: The increasing frequency and size of autochthonous dengue outbreaks in EU/EEA countries presents an emerging challenge for blood safety. Safety measures reported by EU/EEA countries generally address travellers returning from endemic countries outside the EU and only a few countries report measures for travellers returning from affected areas in non-endemic countries. ASSESSMENT Deferral criteria and testing strategies for dengue virus in blood donors returning from affected areas Survey results Deferral criteria and testing strategies for dengue virus in blood donors returning from affected areas ECDC ASSESSMENT 2 Introduction Dengue virus (DENV) is an enveloped, single-stranded, positive RNA virus belonging to the Flaviviridae family, within the Flavivirus genus. There are four distinct serotypes of DENV (DENV-1, DENV-2, DENV-3,